viral
diseas
except
caus
human
immunodefici
viru
selflimit
ill
requir
specif
antivir
therapi
current
avail
antivir
drug
target
main
group
virus
herp
hepat
influenza
virus
except
antisens
molecul
fomivirsen
antiherp
drug
inhibit
viral
replic
serv
competit
substrat
viral
dna
polymeras
drug
treatment
influenza
inhibit
ion
channel
protein
enzym
neuraminidas
combin
therapi
ribavirin
remain
backbon
treatment
chronic
hepat
c
addit
serin
proteas
inhibitor
improv
treatment
outcom
patient
infect
hepat
c
viru
genotyp
chronic
hepat
b
treat
interferon
combin
nucleo
ide
analogu
notabl
almost
nucleo
ide
analogu
treatment
chronic
hepat
b
possess
antihuman
immunodefici
viru
properti
inhibit
replic
hepat
b
viru
serv
competit
substrat
dna
polymeras
antivir
drug
possess
multipl
potenti
clinic
applic
ribavirin
treatment
chronic
hepat
c
respiratori
syncyti
viru
cidofovir
treatment
cytomegaloviru
dna
virus
drug
resist
emerg
threat
clinic
util
antivir
drug
major
mechan
drug
resist
mutat
viral
dna
polymeras
gene
gene
encod
viral
kinas
requir
activ
certain
drug
acyclovir
ganciclovir
widespread
antivir
resist
limit
clinic
util
inhibitor
prevent
treatment
influenza
infect
articl
provid
overview
clinic
avail
antivir
drug
primari
care
physician
special
focu
pharmacolog
clinic
use
advers
effect
viral
thymidin
kinas
tk
subsequ
human
enzym
acyclovirtriphosph
serv
competit
substrat
viral
dna
polymeras
incorpor
dna
chain
result
termin
viral
replic
acyclovir
approv
treatment
primari
recurr
genit
hsv
infect
tabl
topic
acyclovir
may
use
treat
genit
herp
oral
formul
gener
recommend
iv
acyclovir
use
sever
case
suppress
therapi
oral
acyclovir
also
indic
reduc
incid
recurr
genit
herp
oral
acyclovir
modestli
efficaci
orolabi
herp
immunocompet
individu
orolabi
herp
often
selflimit
antivir
treatment
gener
recommend
howev
oral
acyclovir
may
indic
sever
case
recurr
orolabi
herp
immunocompromis
intraven
acyclovir
firstlin
treatment
hsv
enceph
start
soon
diseas
suspect
clinic
magnet
reson
imag
brain
typic
demonstr
tempor
lobe
involv
diagnosi
confirm
detect
hsv
dna
csf
major
studi
evalu
efficaci
day
acyclovir
treatment
hsv
enceph
howev
recommend
durat
treatment
clinic
set
week
shorter
durat
associ
relaps
treatment
durat
may
prolong
immunocompromis
patient
acyclovir
also
approv
us
food
drug
administr
fda
treatment
vzv
howev
young
immunocompet
patient
zoster
may
requir
treatment
lesion
local
present
hour
intraven
acyclovir
recommend
patient
dissemin
zoster
diseas
viscer
involv
acyclovir
treatment
zoster
reduc
durat
viral
shed
format
new
lesion
shortand
longterm
neuralgia
therapi
start
earli
even
delay
initi
acyclovir
may
still
benefici
immunocompromis
patient
shortcours
prednison
may
ad
adjunct
acyclovir
treatment
zoster
improv
qualiti
life
especi
elderli
patient
acyclovir
use
treatment
acut
retin
necrosi
associ
hsv
vzv
eczema
herpeticum
oral
hairi
leukoplakia
due
ebv
oral
acyclovir
use
prevent
hsv
earli
period
transplant
patient
receiv
ganciclovir
valganciclovir
prophylaxi
acyclovir
gener
well
toler
howev
iv
acyclovir
may
caus
revers
nephrotox
patient
intratubular
precipit
acyclovir
crystal
acyclovir
crystallin
nephropathi
common
acyclovir
given
rapid
infus
reach
serum
concentr
mgml
patient
dehydr
preexist
renal
impair
adequ
hydrat
slower
rate
infus
dose
base
renal
function
may
reduc
risk
revers
neurolog
symptom
delirium
seizur
may
occur
rare
elderli
peopl
renal
impair
toxic
associ
high
serum
acyclovir
concentr
high
csf
level
metabolit
advers
effect
gastrointestin
symptom
myelosuppress
rash
acyclovirresist
hsv
report
especi
immunocompromis
patient
resist
occur
select
viral
mutant
defici
tk
result
inabl
activ
acyclovir
alter
dna
polymeras
reduc
affin
acyclovirtriphosph
brivudin
brivudin
thymidin
nucleosid
analogu
highli
activ
vzv
brivudin
phosphoryl
viral
tk
cellular
kinas
brivudintriphosph
serv
competit
inhibitor
viral
dna
polymeras
therebi
termin
viral
dna
synthesi
avail
countri
treatment
herp
zoster
herp
simplex
howev
concern
toxic
halt
clinic
develop
unit
state
metabolit
bromovinyluracil
irrevers
inhibit
dihydropyridin
dehydrogenas
regul
nucleosid
metabol
coadministr
result
lethal
bone
marrow
toxic
sever
gastrointestin
toxic
cidofovir
cidofovir
nucleosid
analogu
use
treatment
cmv
herpesvirus
dna
viral
infect
avail
iv
formul
oral
prodrug
cidofovir
known
clinic
develop
investig
lipid
ester
formul
cidofovir
enhanc
bioavail
result
improv
inhibitori
concentr
direct
intraocular
inject
cidofovir
contraind
due
ocular
hypotoni
serum
cidofovir
concentr
declin
rapidli
iv
infus
halflif
hour
howev
intracellular
halflif
activ
cidofovirdiphosph
long
hour
cidofovir
elimin
glomerular
filtrat
tubular
secret
probenecid
reduc
excret
block
tubular
secret
cidofovir
phosphoryl
cellular
kinas
cidofovirdiphosph
competit
substrat
viral
dna
polymeras
therebi
halt
viral
dna
synthesi
major
clinic
indic
cidofovir
treatment
cmv
retin
hivinfect
patient
tabl
cidofovir
also
use
rescu
therapi
immunocompromis
patient
cmv
diseas
resist
unrespons
ganciclovir
activ
cidofovir
reli
viral
kinas
retain
activ
cmv
mutat
hsv
tk
mutat
resist
cidofovir
occur
viru
develop
mutat
dna
polymeras
gene
ie
gene
person
use
mass
reproduc
permiss
mayo
clinic
proceed
mutat
cidofovir
also
use
offlabel
variou
ill
acyclovirresist
hsv
diseas
condyloma
acuminatum
bk
virusassoci
hemorrhag
cystiti
jc
virusassoci
progress
multifoc
leukoencephalopathi
infect
due
doublestrand
dna
virus
nephrotox
common
seriou
advers
effect
cidofovir
incid
sever
nephrotox
may
reduc
hydrat
probenecid
blood
cell
count
monitor
assess
myelosuppress
ophthalmolog
surveil
recommend
risk
ocular
hypotoni
uveiti
iriti
famciclovir
famciclovir
diacetyl
analogu
penciclovir
oral
famciclovir
rapidli
absorb
achiev
bioavail
famciclovir
metabol
penciclovir
reach
peak
plasma
penciclovir
concentr
within
hour
extens
hepat
metabol
virtual
famciclovir
detect
plasma
famciclovir
excret
renal
penciclovir
precursor
famciclovir
activ
vzv
lesser
extent
ebv
mechan
action
penciclovir
penciclovir
triphosph
inhibit
herp
dna
synthesi
act
substrat
viral
dna
polymeras
major
clinic
indic
famciclovir
use
treatment
herp
zoster
recurr
genit
herp
recurr
herp
labiali
famciclovir
also
use
suppress
therapi
reduc
risk
recurr
genit
herp
well
oral
treatment
uncompl
varicella
hivinfect
patient
common
advers
effect
famciclovir
headach
nausea
rare
advers
event
includ
jaundic
rash
pruritu
somnol
confus
acut
renal
failur
occur
patient
take
inappropri
high
dose
famciclovir
fomivirsen
fomivirsen
phosphorothion
oligonucleotid
complementari
messeng
rna
mrna
immediateearli
region
cmv
antivir
properti
exert
antisens
inhibit
target
gene
express
potenti
mechan
antivir
activ
includ
nonspecif
interact
viral
particl
may
prevent
adsorpt
lead
inhibit
enzym
requir
viral
dna
synthesi
fomivirsen
given
intravitr
main
indic
treatment
cmv
retin
patient
aid
benefit
intoler
standard
cmv
therapi
whose
viru
resist
ganciclovir
foscarnet
main
advers
effect
fomivirsen
increas
intraocular
pressur
inflamm
blur
vision
conjunctiv
hemorrhag
retin
detach
retin
edema
advers
effect
foscarnet
foscarnet
nonnucleosid
pyrophosph
analogu
given
intraven
treatment
herpesvirus
pharmacokinet
profil
complic
high
incid
nephrotox
deposit
subsequ
gradual
releas
bone
halflif
depend
durat
therapi
patient
normal
renal
function
plasma
halflif
hour
termin
halfliv
day
may
occur
accumul
bone
foscarnet
excret
glomerular
filtrat
foscarnet
select
inhibit
pyrophosph
bind
viral
dna
polymeras
thu
suppress
cmv
replic
also
activ
vzv
ebv
unlik
ganciclovir
foscarnet
requir
intracellular
convers
activ
triphosph
thu
maintain
activ
herpesvirus
tk
kinas
mutat
foscarnet
approv
treatment
cmv
retin
patient
aid
use
treat
cmv
diseas
immunocompromis
patient
especi
unabl
toler
ganciclovir
infect
ganciclovirresist
viru
foscarnet
also
use
treat
acyclovirresist
mucocutan
hsv
vzv
immunocompromis
patient
rare
occas
use
prevent
cmv
transplant
recipi
howev
toxic
limit
clinic
indic
nephrotox
common
seriou
advers
effect
foscarnet
affect
patient
caus
deposit
foscarnet
crystal
glomerular
capillari
lumen
foscarnet
may
caus
myelosuppress
anemia
common
effect
chelat
bival
metal
ion
may
lead
reduct
ioniz
calcium
electrolyt
disturb
hypokalemia
hypomagnesemia
hypophosphatasemia
could
manifest
paresthesia
cardiac
dysrhythmia
neurolog
symptom
includ
seizur
patient
hydrat
prevent
nephrotox
electrolyt
abnorm
correct
avoid
cardiac
neurolog
complic
ganciclovir
acycl
analogu
manag
cmv
avail
oral
parenter
formul
oral
ganciclovir
poorli
absorb
bioavail
manag
activ
cmv
diseas
therefor
iv
ganciclovir
oral
valyl
prodrug
valganciclovir
intravitr
ganciclovir
imfor
person
use
mass
reproduc
permiss
mayo
clinic
proceed
plant
also
avail
minim
system
absorpt
ganciclovir
excret
renal
ganciclovir
undergo
triphosphoryl
becom
activ
initi
monophosphoryl
catalyz
kinas
subsequ
cellular
kinas
ganciclovir
triphosph
inhibit
viral
dna
synthesi
competit
incorpor
viral
dna
synthesi
therebi
lead
dna
chain
termin
vitro
time
potent
acyclovir
cmv
ebv
effect
acyclovir
vzv
ganciclovir
activ
ganciclovir
approv
treatment
cmv
retin
patient
aid
treatment
herp
simplex
kerat
cmv
prophylaxi
transplant
recipi
intraven
ganciclovir
may
also
use
treat
form
cmv
diseas
coliti
esophag
induct
therapi
iv
ganciclovir
cmv
retin
patient
aid
efficaci
stabil
diseas
poorli
absorb
oral
ganciclovir
use
induct
treatment
cmv
diseas
cmv
diseas
often
recur
progress
patient
advanc
aid
oral
iv
ganciclovir
valganciclovir
given
mainten
therapi
immun
reconstitut
achiev
intravitr
ganciclovir
may
also
surgic
implant
treatment
cmv
retin
although
treatment
use
togeth
system
therapi
iv
ganciclovir
oral
valganciclovir
therapi
oral
ganciclovir
may
use
prevent
cmv
patient
aid
howev
benefit
strategi
pronounc
era
highli
activ
antiretrovir
therapi
although
iv
oral
ganciclovir
also
use
prevent
cmv
diseas
transplant
recipi
valganciclovir
current
prefer
drug
indic
intraven
ganciclovir
also
use
firstlin
treatment
cmv
diseas
bone
marrow
solid
organ
transplant
recipi
revers
bone
marrow
suppress
common
advers
effect
ganciclovir
advers
effect
drug
rash
pruritu
diarrhea
nausea
vomit
increas
level
serum
creatinin
liver
enzym
neurotox
may
occur
occasion
resist
ganciclovir
occur
commonli
sever
immunocompromis
patient
prolong
exposur
drug
common
mechan
ganciclovir
resist
gene
mutat
mutat
lead
defici
viral
kinas
necessari
initi
phosphoryl
ganciclovir
activ
form
less
common
mechan
mutat
gene
encod
cmv
dna
polymeras
penciclovir
acycl
guanin
analogu
chemic
similar
acyclovir
poorli
absorb
gastrointestin
tract
avail
topic
therapi
mucocutan
herp
system
use
penciclovir
reformul
oral
prodrug
famciclovir
antivir
activ
penciclovir
similar
acyclovir
efficaci
vzv
lesser
extent
ebv
penciclovir
monophosphoryl
tk
subsequ
cellular
kinas
activ
penciclovirtriphosph
inhibit
herp
dna
polymeras
activ
serv
competit
inhibitor
deoxyguanosin
triphosph
penciclovir
approv
topic
therapi
recurr
herp
labiali
result
faster
heal
rate
reduct
pain
viral
shed
valacyclovir
valacyclovir
lvalyl
ester
prodrug
acyclovir
provid
higher
bioavail
oral
acyclovir
absorpt
valacyclovir
hydrolyz
almost
complet
acyclovir
firstpass
intestin
hepat
metabol
achiev
peak
serum
concentr
hour
serum
acyclovir
level
much
higher
valacyclovir
oral
acyclovir
mechan
action
spectrum
activ
valacyclovir
ident
acyclovir
approv
treatment
initi
recurr
episod
genit
herp
treatment
recurr
herp
labiali
treatment
efficaci
initi
earliest
onset
symptom
suppress
therapi
valacyclovir
recommend
prevent
recurr
genit
herp
potenti
reduc
transmiss
sexual
partner
valacyclovir
approv
treatment
vzv
varicella
often
resolv
without
antivir
therapi
immunocompet
howev
immunocompromis
patient
hivinfect
patient
transplant
recipi
valacyclovir
may
use
treat
varicella
even
uncompl
valacyclovir
commonli
use
drug
treatment
zoster
random
doubleblind
trial
older
immunocompet
patient
valacyclovir
effect
acyclovir
similar
resolut
rate
cutan
zoster
acceler
resolut
herpet
pain
lower
risk
postherpet
neuralgia
typic
cours
zoster
treatment
day
first
dose
start
within
hour
rash
onset
treatment
prolong
continu
lesion
crust
immunocompromis
patient
valacyclovir
also
use
treat
acut
retin
necrosi
prevent
cmv
diseas
kidney
howev
valacyclovir
proven
effect
prevent
cmv
heart
liver
lung
pancrea
small
bowel
transplant
recipi
advers
effect
valacyclovir
similar
acyclovir
high
dose
neurotox
character
confus
hallucin
seizur
may
occur
especi
elderli
patient
dehydr
renal
diseas
mechan
resist
valacyclovir
ident
acyclovir
tk
mutat
howev
achiev
higher
serum
acyclovir
level
valacyclovir
could
reduc
risk
resist
compar
oral
acyclovir
valganciclovir
valganciclovir
lvalyl
ester
prodrug
ganciclovir
oral
valganciclovir
well
absorb
convert
ganciclovir
firstpass
intestin
hepat
metabol
bioavail
ganciclovir
valganciclovir
administr
peak
plasma
concentr
achiev
hour
valganciclovir
elimin
renal
ganciclovir
valganciclovir
exert
antivir
activ
form
ganciclovirtriphosph
inhibit
viral
replic
serv
competit
substrat
cmv
dna
polymeras
valganciclovir
first
approv
fda
treatment
cmv
retin
patient
aid
immedi
sightthreaten
lesion
valganciclovir
use
combin
intravitr
ganciclovir
implant
valganciclovir
also
use
prevent
cmv
diseas
highrisk
cmv
donorpositiverecipientneg
recipi
kidney
heart
kidneypancrea
transplant
unit
state
valganciclovir
approv
prevent
cmv
diseas
liver
recipi
higher
incid
tissueinvas
cmv
diseas
patient
receiv
valganciclovir
vs
oral
ganciclovir
prophylaxi
countri
valganciclovir
use
prevent
cmv
diseas
solid
organ
transplant
recipi
recent
gain
approv
prevent
cmv
diseas
pediatr
heart
kidney
transplant
recipi
also
use
preemptiv
treat
asymptomat
cmv
infect
transplant
recipi
valganciclovir
recent
demonstr
effect
iv
ganciclovir
treat
mild
moder
cmv
diseas
transplant
recipi
bone
marrow
suppress
common
advers
effect
valganciclovir
gastrointestin
manifest
diarrhea
nausea
vomit
may
observ
resist
valganciclovir
occur
mechan
ident
underli
ganciclovir
resist
ie
mutat
gene
encod
cmv
kinas
gene
encod
cmv
dna
polymeras
vidarabin
vidarabin
purin
nucleosid
obtain
streptomyc
antibioticu
histor
use
treat
hsv
vzv
acyclovir
sinc
becom
prefer
drug
condit
vidarabin
current
avail
ophthalm
solut
treat
recurr
epitheli
kerat
acut
keratoconjunct
phosphoryl
activ
form
vidarabin
inhibit
viral
dna
polymeras
advers
effect
ophthalm
vidarabin
includ
irrit
pain
photophobia
lacrim
occlus
lacrim
duct
amantadin
amantadin
symmetr
tricycl
amin
inhibit
replic
influenza
viru
impair
function
membran
protein
present
influenza
viru
acidactiv
ion
channel
requir
nucleocapsid
releas
amantadin
well
absorb
oral
administr
elimin
halflif
hour
excret
glomerular
filtrat
tubular
secret
amantadin
effect
treat
suscept
influenza
viru
infect
result
rapid
function
recoveri
reduc
durat
fever
symptom
day
given
within
hour
diseas
onset
amantadin
effect
prophylaxi
prevent
symptomat
influenza
infect
expos
person
usual
given
day
least
day
last
confirm
ill
season
influenza
vaccin
howev
remain
prefer
method
prevent
amantadin
gener
well
toler
among
advers
effect
mild
neurolog
symptom
anxieti
disorient
headach
especi
elderli
patient
take
neuroaffect
drug
emerg
amantadin
resist
limit
use
clinic
set
amantadin
resist
character
amino
acid
substitut
protein
emerg
within
day
treatment
widespread
resist
amantadin
longer
recommend
empir
treatment
influenza
mutat
confer
crossresist
rimantadin
rimantadin
rimantadin
symmetr
tricycl
amin
inhibit
influenza
viru
well
absorb
oral
administr
reach
peak
plasma
concentr
person
use
mass
reproduc
permiss
mayo
clinic
proceed
hour
rimantadin
undergo
extens
hepat
metabol
excret
urin
mechan
action
rimantadin
similar
amantadin
inhibit
ion
channel
function
therebi
inhibit
viral
uncoat
rimantadin
indic
prevent
treatment
influenza
viru
howev
clinic
util
current
limit
drug
resist
trial
compar
amantadin
rimantadin
suggest
similar
efficaci
howev
neurolog
advers
event
less
sever
frequent
rimantadin
oseltamivir
oseltamivir
phosphat
prodrug
oseltamivir
carboxyl
inhibitor
neuraminidas
essenti
replic
influenza
b
virus
oral
oseltamivir
well
absorb
reach
peak
serum
concentr
hour
bioavail
oseltamivir
phosphat
least
prodrug
oseltamivir
phosphat
undergo
extens
hepat
metabol
via
ester
hydrolysi
activ
oseltamivir
carboxyl
excret
renal
oseltamivir
carboxyl
activ
drug
metabolit
select
block
viral
neuraminidas
therebi
prevent
releas
viru
infect
cell
oseltamivir
approv
treatment
children
year
adult
influenza
b
viral
infect
treatment
start
within
hour
diseas
onset
continu
day
oseltamivir
effect
neuraminidas
inhibitor
zanamivir
reduc
febril
period
infect
influenza
influenza
influenza
b
viru
oseltamivir
also
use
postexposur
prophylaxi
influenza
b
includ
pandem
strain
indic
oseltamivir
start
within
hour
exposur
continu
daili
least
day
week
outbreak
systemat
review
report
statist
signific
differ
oseltamivir
zanamivir
prophylaxi
prevent
symptomat
influenza
among
immunocompet
adult
common
advers
effect
oseltamivir
nausea
vomit
diarrhea
abdomin
pain
insomnia
vertigo
neuropsychiatr
advers
effect
includ
delirium
abnorm
behavior
hallucin
report
oseltamivirresist
influenza
viru
report
mutat
neuraminidas
gene
account
oseltamivir
resist
surveil
conduct
influenza
pandem
detect
sporad
infrequ
incid
oseltamivirresist
pandem
influenza
viru
resist
virus
neuraminidas
mutat
commonli
mutat
confer
resist
oseltamivir
zanamivir
oseltamivir
resist
among
influenza
b
virus
occur
less
frequent
zanamivir
zanamivir
inhal
neuraminidas
inhibitor
use
treatment
prophylaxi
influenza
b
virus
zanamivir
avail
oral
sinc
poorli
absorb
inhal
zanamivir
produc
high
concentr
respiratori
tract
influenza
viru
infect
occur
inhal
zanamivir
absorb
system
produc
peak
serum
concentr
hour
absorb
drug
metabol
excret
unchang
urin
unabsorb
drug
excret
fece
mechan
action
zanamivir
similar
oseltamivir
inhibit
neuraminidas
essenti
releas
newli
form
viral
particl
infect
cell
treatment
zanamivir
given
inhal
twice
daili
day
therapi
begun
within
hour
symptom
onset
zanamivir
given
daili
day
postexposur
prophylaxi
influenza
b
household
close
contact
zanamivir
prophylaxi
commun
outbreak
may
given
day
zanamivir
occasion
given
iv
treat
critic
ill
patient
influenza
inhal
zanamivir
well
toler
acut
bronchospasm
declin
respiratori
function
report
bronchodil
avail
given
treatment
patient
underli
pulmonari
diseas
advers
effect
includ
headach
gastrointestin
symptom
hypersensit
reaction
neuropsychiatr
advers
effect
occur
rare
interferon
interferon
ifn
natur
occur
protein
produc
respons
viral
infect
major
class
ifn
classifi
type
wherea
type
ii
avail
parenter
formul
subcutan
sc
intramuscular
dose
absorb
intramuscular
inject
peak
ifn
concentr
occur
within
hour
return
baselin
level
hour
pegyl
process
attach
ifn
larg
inert
polyethylen
glycol
markedli
reduc
rate
absorpt
excret
ifn
therefor
increas
plasma
concentr
exampl
sc
dose
peginterferon
peak
serum
concentr
occur
hour
high
concentr
maintain
hour
mean
termin
halflif
hour
contrast
peak
serum
concentr
peginterferon
reach
hour
sc
dose
mean
termin
halflif
hour
undergo
extens
renal
catabol
neglig
amount
ifn
excret
urin
interferon
multipl
overlap
biolog
activ
includ
antivir
antiprolif
immunoregulatori
function
bind
receptor
ifn
initi
cascad
event
lead
variou
cellular
respons
inhibit
viru
replic
suppress
cell
prolifer
enhanc
phagocyt
activ
macrophag
augment
specif
cytotox
lymphocyt
target
cell
interferon
use
treat
multipl
viral
infect
commonli
use
treat
chronic
viral
hepat
first
drug
approv
treatment
compens
liver
diseas
due
chb
approv
treat
acut
hepat
b
chb
ifn
given
parenter
depend
dose
schedul
month
week
interferon
effect
patient
recent
acquir
hepat
b
viru
hbv
high
pretreat
level
alanin
aminotransferas
alt
low
level
hbv
dna
subcutan
effect
slightli
effect
sc
likewis
sc
may
effect
lamivudin
hepat
b
e
antigen
hbeag
posit
hbeagneg
patient
chb
addit
lamivudin
significantli
enhanc
efficaci
effect
patient
hbv
hepat
viru
coinfect
although
less
respons
patient
infect
hbv
alon
guidelin
manag
chb
hivinfect
patient
recent
publish
patient
requir
antihiv
therapi
month
consid
therapeut
option
lamivudin
antivir
nucleo
ide
treatment
hbv
often
antihiv
properti
may
result
develop
hiv
resist
given
monotherapi
hbvhiv
coinfect
patient
approv
treatment
chronic
hepat
c
chc
howev
approv
acut
hepat
c
metaanalysi
found
least
month
best
riskbenefit
ratio
patient
chc
onceweekli
effect
given
time
weekli
patient
chc
howev
combin
therapi
oral
ribavirin
effect
either
drug
use
alon
combin
oral
ribavirin
may
effect
combin
therefor
british
societi
gastroenterolog
american
associ
studi
liver
diseas
recommend
onceweekli
sc
combin
oral
ribavirin
first
line
treatment
chc
recommend
durat
treatment
chc
patient
infect
hiv
week
hepat
c
viru
hcv
genotyp
week
hcv
genotyp
patient
coinfect
hiv
hcv
rate
intoler
combin
regimen
ribavirin
higher
rate
sustain
virolog
respons
svr
lower
patient
infect
hcv
alon
use
result
higher
svr
rate
use
apricot
studi
report
svr
rate
patient
treat
plu
ribavirin
compar
treat
monotherapi
treat
plu
ribavirin
lower
svr
rate
combin
plu
ribavirin
therapi
observ
patient
coinfect
hcv
genotyp
hcv
genotyp
guidelin
manag
hiv
hcv
coinfect
publish
recent
gener
guidelin
recommend
combin
therapi
ribavirin
week
interferon
gener
recommend
acut
viral
hepat
treatment
acut
hcv
result
rapid
resolut
viremia
reduc
progress
chronic
hepat
american
associ
studi
liver
diseas
recommend
either
least
month
acut
hcv
infect
persist
month
diagnosi
interferon
also
approv
intralesion
therapi
condyloma
acuminatum
genit
perian
area
intralesion
inject
ensur
rel
high
concentr
ifn
local
site
infect
occurr
system
advers
effect
suggest
absorpt
site
current
hsv
gener
treat
acyclovir
benefici
respons
topic
report
genit
herp
hsv
kerat
benefici
respons
report
hivassoci
progress
multifoc
leukoencephalopathi
howev
find
debat
may
provid
ad
benefit
use
highli
activ
antiretrovir
therapi
patient
receiv
ifn
may
develop
flulik
symptom
appear
doserel
like
occur
start
treatment
typic
respond
acetaminophen
among
seriou
advers
effect
neuropsychiatr
disord
eg
depress
homicid
suicid
ideat
neurolog
disturb
eg
confus
seizur
myelosuppress
neutropenia
commonli
aplast
anemia
rare
cardiovascular
disord
eg
arrhythmia
endocrin
disord
eg
thyroid
disord
pulmonari
disord
eg
dyspnea
pneumon
patient
risk
develop
depress
preexist
mood
anxieti
disfor
person
use
mass
reproduc
permiss
mayo
clinic
proceed
order
histori
major
depress
receiv
higher
dose
undergo
longterm
treatment
regimen
select
serotonin
reuptak
inhibitor
use
success
treat
patient
ifnassoci
depress
allow
therapi
continu
pretreat
prevent
occurr
highrisk
patient
advers
effect
alter
liver
function
renal
insuffici
gastrointestin
manifest
ribavirin
ribavirin
synthet
nucleosid
analogu
guanin
avail
oral
aerosol
iv
formul
oral
ribavirin
absorb
extens
bioavail
firstpass
metabol
peak
plasma
ribavirin
concentr
occur
within
hour
oral
dose
peak
plasma
concentr
increas
time
time
higher
week
treatment
administr
aerosol
ribavirin
lead
high
concentr
respiratori
tract
ribavirin
absorb
system
ribavirin
mainli
excret
urin
mechan
action
ribavirin
known
divers
complet
understood
may
competit
inhibitor
cellular
enzym
antivir
activ
revers
guanosin
triphosphoryl
form
ribavirin
triphosph
potent
competit
inhibitor
inosin
monophosph
dehydrogenas
influenza
viru
rna
polymeras
mrna
guanylyltransferas
result
competit
inhibit
intracellular
guanosin
triphosph
pool
markedli
reduc
viral
nucleic
acid
protein
synthesi
inhibit
ribavirin
alter
viral
attach
penetr
uncoat
induc
ifn
product
ribavirin
inhibit
multipl
virus
vitro
among
suscept
dna
virus
herpesvirus
adenovirus
poxvirus
suscept
rna
virus
includ
hcv
lassa
viru
influenza
parainfluenza
measl
mump
rsv
hiv
howev
correl
found
ribavirin
vitro
activ
activ
human
infect
oral
ribavirin
approv
use
combin
treatment
chc
howev
effect
given
monotherapi
durat
treatment
sometim
dose
may
dictat
hcv
genotyp
treatment
infect
hcv
genotyp
probabl
genotyp
gener
continu
week
wherea
genotyp
may
treat
week
treatment
hcv
patient
coinfect
hiv
week
ribavirin
approv
treatment
rsv
children
includ
hematopoiet
stem
cell
transplant
recipi
use
treatment
rsv
pneumonia
ribavirin
usual
given
aerosol
rout
deliv
high
concentr
site
infect
oral
ribavirin
also
use
good
outcom
ribavirin
use
offlabel
treatment
hsv
influenza
sever
acut
respiratori
syndrom
coronaviru
la
cross
enceph
nipah
enceph
lassa
fever
hemorrhag
fever
renal
syndrom
crimeancongo
hemorrhag
fever
bolivian
hemorrhag
fever
hantaviru
pulmonari
syndrom
aerosol
ribavirin
caus
sudden
deterior
respiratori
function
cardiovascular
effect
precipit
inhal
ribavirin
may
occur
ventilatori
tube
hemolyt
anemia
occur
commonli
ribavirin
given
patient
preexist
medic
condit
exacerb
ribavirininduc
hemolysi
includ
signific
cardiac
diseas
hemoglobinopathi
sever
depress
suicid
ideat
relaps
drug
abus
may
occur
ribavirin
contraind
patient
histori
exist
psychiatr
disord
signific
teratogen
andor
embryocid
effect
observ
anim
expos
ribavirin
ribavirin
therefor
contraind
pregnant
women
male
partner
recommend
patient
use
form
contracept
avoid
pregnanc
therapi
month
thereaft
addit
ifn
sever
nucleo
ide
analogu
avail
treatment
chb
tabl
except
telbivudin
drug
possess
antihiv
properti
serv
inhibitor
hiv
revers
transcriptas
inhibitor
specif
mechan
antihbv
properti
competit
inhibit
hbv
dna
polymeras
antihiv
properti
highli
recommend
chb
patient
consid
treatment
drug
test
hiv
infect
monotherapi
drug
avoid
hivinfect
patient
reduc
risk
hiv
resist
hepat
b
viru
may
also
develop
resist
drug
usual
prolong
exposur
risk
may
reduc
strategi
combin
antivir
therapi
exact
durat
antihbv
treatment
defin
hbv
relaps
often
occur
discontinu
treatment
sever
exacerb
hepat
may
also
occur
discontinu
drug
henc
monitor
hepatotox
perform
stop
treatment
lactic
acidosi
may
occur
nucleo
ide
analogu
drug
withdrawn
rapid
increas
alt
level
progress
hepatomegali
steatosi
acidosi
adefovir
adefovir
dipivoxil
acycl
nucleotid
analogu
adenosin
monophosph
oral
adefovir
dipivoxil
rapidli
absorb
convert
adefovir
oral
bioavail
excret
drug
glomerular
filtrat
activ
tubular
secret
adefovir
convert
intracellularli
cellular
kinas
activ
metabolit
adefovir
diphosph
competit
inhibit
hbv
dna
polymeras
although
adefovir
distinct
least
potent
among
current
avail
antihbv
drug
use
adult
decompens
liver
diseas
compens
liver
diseas
evid
activ
viral
replic
persist
elev
alt
level
histolog
evid
activ
inflamm
fibrosi
major
advers
effect
adefovir
nephrotox
includ
proxim
renal
tubular
dysfunct
fanconi
syndrom
gastrointestin
symptom
nausea
diarrhea
abdomin
pain
may
observ
adefovir
resist
character
mutat
gradual
increas
time
year
respect
minim
risk
resist
adefovir
use
combin
drug
lamivudin
howev
concomit
use
relat
drug
tenofovir
disoproxil
fumar
recommend
augment
risk
nephrotox
emtricitabin
emtricitabin
analogu
cytidin
although
current
approv
treatment
chb
emtricitabin
use
clinic
combin
tenofovir
hivhbvcoinfect
patient
emtricitabin
similar
lamivudin
crossresist
drug
common
emtricitabin
may
potent
lamivudin
howev
use
monotherapi
high
rate
resist
develop
rate
emtricitabin
resist
among
patient
hbv
monoinfect
week
advers
effect
reportedli
uncommon
includ
mild
moder
headach
nausea
diarrhea
rash
entecavir
entecavir
nucleosid
guanosin
analogu
consid
one
potent
agent
treatment
patient
chb
includ
resist
lamivudin
oral
entecavir
extens
absorb
peak
plasma
concentr
occur
minut
oral
bioavail
almost
despit
low
plasma
concentr
entecavir
maintain
potenc
long
intracellular
halflif
activ
metabolit
entecavir
triphosph
entecavir
mainli
excret
glomerular
filtrat
activ
tubular
secret
mechan
action
entecavir
somewhat
uniqu
inhibit
specif
function
hbv
dna
polymeras
prime
hbv
dna
polymeras
revers
transcript
neg
strand
pregenom
mrna
synthesi
positivestrand
hbv
dna
entecavir
approv
treatment
chb
dose
mg
oral
daili
nucleosid
person
use
mass
reproduc
permiss
mayo
clinic
proceed
treatmentna
patient
dose
mg
oral
daili
patient
histori
hbv
viremia
receiv
lamivudin
lamivudineor
telbivudineresist
mutat
decompens
liver
diseas
random
trial
hbeagposit
hbeagneg
patient
entecavir
demonstr
better
outcom
lamivudin
improv
histolog
respons
higher
percentag
hbv
dna
suppress
normal
improv
alt
level
advers
effect
entecavir
gener
mild
includ
headach
fatigu
nausea
diarrhea
insomnia
entecavir
high
barrier
resist
requir
least
mutat
phenotyp
resist
entecavir
resist
requir
baselin
mutat
plu
either
among
nucleosidena
patient
rate
entecavir
resist
less
year
patient
preexist
higher
rate
entecavir
resist
year
lamivudin
lamivudin
nucleosid
analogu
cytosin
oral
lamivudin
provid
bioavail
peak
serum
concentr
occur
hour
hepat
metabol
low
excret
unchang
kidney
lamivudin
phosphoryl
intracellularli
activ
metabolit
lamivudin
triphosph
activ
metabolit
incorpor
viral
dna
hbv
polymeras
result
dna
chain
termin
lamivudin
first
drug
use
alter
nativ
treatment
chb
doubleblind
studi
involv
patient
chb
lamivudin
associ
substanti
histolog
improv
hbeag
antibodi
seroconvers
alt
normal
howev
relaps
common
treatment
discontinu
advers
effect
lamivudin
mild
includ
abdomin
pain
nausea
headach
clinic
util
lamivudin
limit
rapid
develop
antivir
resist
lamivudin
share
lnucleosid
primari
resist
mutat
occur
easili
confer
crossresist
year
lamivudin
monotherapi
resist
develop
patient
hbv
monoinfect
hivhbv
coinfect
respect
telbivudin
telbivudin
synthet
thymidin
nucleosid
analogu
unlik
antihbv
drug
telbivudin
activ
hiv
oral
telbivudin
well
absorb
achiev
peak
plasma
concentr
hour
mainli
excret
glomerular
filtrat
termin
elimin
halflif
hour
telbivudinetriphosph
inhibit
hbv
competit
inhibit
viral
dna
polymeras
oral
telbivudin
approv
treatment
chb
patient
compens
liver
diseas
evid
activ
viral
replic
persist
increas
serum
alt
concentr
histolog
evid
activ
liver
inflamm
fibrosi
consid
effect
lamivudin
adefovir
compar
lamivudin
telbivudin
associ
higher
degre
reduct
hbv
dna
level
howev
signific
differ
found
alt
level
normal
loss
hbeag
antihb
seroconvers
common
advers
effect
report
telbivudin
dizzi
fatigu
gastrointestin
symptom
rash
uniqu
advers
effect
peripher
neuropathi
myopathi
elev
creatin
kinas
level
telbivudin
treatment
discontinu
either
peripher
neuropathi
myopathi
diagnos
rate
resist
telbivudin
week
treatment
tenofovir
tenofovir
disoproxil
fumar
acycl
nucleosid
phosphon
diester
analogu
adenosin
monophosph
consid
one
potent
antihbv
drug
oral
form
rapidli
absorb
convert
tenofovir
reach
peak
plasma
concentr
hour
oral
bioavail
fast
state
enhanc
taken
highfat
meal
termin
elimin
halflif
tenofovir
hour
excret
mainli
activ
tubular
secret
glomerular
filtrat
tenofovir
disoproxil
fumar
prodrug
requir
diester
hydrolysi
convers
tenofovir
subsequ
phosphoryl
cellular
enzym
form
tenofovir
diphosph
compet
natur
substrat
deoxyadenosin
incorpor
viral
dna
strand
tenofovir
use
treatment
chb
random
trial
compar
tenofovir
adefovir
higher
percentag
patient
receiv
tenofovir
achiev
hbv
dna
level
suppress
hbeagposit
patient
biochem
respons
higher
tenofovir
howev
antihb
seroconvers
rate
histolog
respons
similar
adefovir
tenofovir
advers
effect
tenofovir
includ
gastrointestin
symptom
dizzi
fatigu
headach
renal
toxic
includ
nephriti
proxim
renal
tubulopathi
includ
fanconi
syndrom
renal
failur
associ
tenofovir
primari
tenofovir
resist
mutat
well
defin
although
virus
resist
tenofovir
slower
respons
wildtyp
virus
one
studi
report
tenofovir
person
use
mass
reproduc
permiss
mayo
clinic
proceed
sistanc
mutat
howev
pattern
confirm
studi
current
standard
treatment
chc
combin
ribavirin
week
hcv
genotyp
week
hcv
genotyp
major
aim
treatment
achiev
svr
defin
undetect
hcv
rna
week
complet
treatment
combin
regimen
ribavirin
result
svr
rate
rate
even
lower
among
black
patient
henc
major
effort
made
develop
novel
therapi
chc
recent
serin
proteas
inhibitor
approv
novel
therapi
chc
due
genotyp
infect
addit
serin
proteas
inhibitor
backbon
therapi
ribavirin
emerg
standard
care
hcv
genotyp
infect
treatmentna
treatmentexperienc
patient
boceprevir
boceprevir
linear
peptidomimet
ketoamid
serin
proteas
inhibitor
recent
approv
treatment
chc
particularli
genotyp
avail
oral
formul
time
peak
concentr
oral
administr
hour
food
enhanc
absorpt
boceprevir
metabol
primarili
liver
elimin
halflif
hour
excret
mostli
fece
boceprevir
exert
antihcv
properti
bind
revers
hcv
nonstructur
protein
ultim
inhibit
viral
replic
recent
conduct
phase
intern
random
placebocontrol
trial
enrol
previous
untreat
black
nonblack
adult
hcv
genotyp
infect
serin
proteas
inhibitor
therapi
trial
addit
boceprevir
week
week
standard
therapi
ribavirin
result
significantli
higher
svr
rate
compar
standard
therapi
alon
nonblack
cohort
vs
respect
black
cohort
vs
respect
rel
increas
svr
rate
nonblack
cohort
respect
compar
standard
therapi
hcv
retreat
hcv
serin
proteas
inhibitor
boceprevir
pegintronrebetol
trial
evalu
boceprevir
treatment
patient
experienc
relaps
achiev
svr
peginterferonribavirin
treatment
random
openlabel
trial
enrol
patient
svr
rate
significantli
higher
patient
receiv
peginterferonribavirin
plu
boceprevir
treatment
week
week
compar
standard
peginterferonribavirin
treatment
alon
multivari
stepwis
logist
regress
analysi
baselin
factor
associ
svr
boceprevir
use
previou
relaps
compar
previou
nonrespond
low
viral
load
baselin
absenc
cirrhosi
boceprevir
mg
time
daili
approv
fda
first
hcv
proteas
inhibitor
treatment
chc
specif
genotyp
combin
peginterferon
ribavirin
common
advers
effect
boceprevir
flulik
ill
fatigu
nausea
dysgeusia
anemia
addit
boceprevir
nearli
doubl
rate
anemia
compar
use
standard
peginterferon
ribavirin
therapi
mani
patient
requir
use
erythropoietin
telaprevir
telaprevir
oral
avail
inhibitor
specif
hcv
nonstructur
serin
proteas
inhibit
hcv
replic
bind
revers
nonstructur
serin
proteas
oral
administr
telaprevir
achiev
peak
plasma
concentr
hour
metabol
primarili
liver
elimin
halflif
hour
drug
excret
fece
earlyphas
studi
demonstr
potent
antihcv
properti
telaprevir
recent
phase
intern
random
doubleblind
placebocontrol
clinic
trial
addit
telaprevir
standard
treatment
peginterferonribavirin
associ
significantli
higher
svr
rate
compar
standard
peginterferonribavirin
alon
cohort
patient
previous
untreat
hcv
genotyp
infect
specif
group
patient
receiv
week
telaprevir
combin
peginterferonribavirin
follow
peginterferonribavirin
week
hcv
rna
undetect
week
week
hcv
rna
still
detect
week
svr
rate
vs
standard
therapi
svr
rate
also
significantli
higher
compar
standard
therapi
among
patient
receiv
week
telaprevir
combin
peginterferonribavirin
vs
second
random
phase
trial
evalu
telaprevir
treatmentexperienc
patient
hcv
genotyp
infect
addit
telaprevir
standard
treatment
regimen
ribavirin
associ
significantli
higher
svr
rate
compar
standard
regimen
peginterferonribavirin
alon
collect
studi
indic
addit
telaprevir
standard
peginterferonribavirin
therapi
significantli
improv
svr
rate
treatmentna
patient
infect
hcv
genotyp
benefit
initi
treatment
ribavirin
result
find
fda
approv
telaprevir
mg
time
daili
treatment
person
use
mass
reproduc
permiss
mayo
clinic
proceed
indic
common
advers
effect
anemia
neutropenia
leukopenia
rash
one
studi
patient
report
kind
rash
rash
mild
sever
stevensjohnson
syndrom
drug
rash
eosinophilia
system
symptom
report
telaprevir
therapi
discontinu
dermatolog
complic
occur
especi
case
sever
rash
even
mild
moder
rash
accompani
system
symptom
mechan
underli
rash
develop
unknown
fatigu
pruritu
gastrointestin
sympotom
eg
nausea
diarrhea
tast
disturb
may
also
observ
conclus
review
highlight
pharmacokinet
mechan
action
clinic
indic
advers
effect
clinic
avail
drug
manag
virus
hiv
current
avail
antivir
drug
target
main
group
virus
herp
hepat
influenza
virus
antivir
therapeut
armamentarium
evolv
year
rapidli
expand
old
antivir
drug
retain
clinic
util
infect
acyclovir
herp
simplex
viru
ganciclovir
cmv
howev
old
antivir
drug
eg
amantadin
rimantadin
influenza
viru
infect
lost
clinic
util
rapid
widespread
develop
resist
serv
catalyst
develop
novel
therapi
importantli
urg
medic
commun
use
drug
optim
clinic
set
inde
increas
resist
observ
neuraminidas
inhibitor
treatment
influenza
virus
nucleo
ide
analogu
treatment
chb
novel
therapi
develop
eg
serin
proteas
inhibitor
treatment
chc
care
must
taken
optim
use
clinic
life
span
drug
abbrevi
develop
resist
symposium
antimicrobi
therapi
continu
upcom
issu
contribut
symposium
antimicrobi
therapi
cme
activ
cme
credit
see
link
web
site
mayoclinicproceedingscom
